UBE2E2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09311(UBE2E2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The UBE2E2 antibody targets the ubiquitin-conjugating enzyme E2 E2 (UBE2E2), a member of the E2 enzyme family critical in the ubiquitin-proteasome system (UPS). UBE2E2 facilitates the transfer of ubiquitin to substrate proteins, a process mediated by E3 ligases, marking targets for degradation or functional modification. This enzyme plays roles in cellular processes like protein turnover, DNA repair, and regulation of signaling pathways. Dysregulation of UBE2E2 has been implicated in diseases such as cancer, neurodegenerative disorders, and metabolic syndromes, where UPS dysfunction contributes to pathogenesis.

Antibodies against UBE2E2 are essential tools for studying its expression, localization, and interactions. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into its mechanistic roles. Studies using UBE2E2 antibodies have linked its overexpression to tumor progression in certain cancers, while reduced levels are observed in conditions like diabetes, suggesting tissue-specific regulatory functions.

Developing specific UBE2E2 antibodies remains challenging due to homology within the E2 family. However, well-validated antibodies are crucial for elucidating UBE2E2's post-translational modifications, substrate specificity, and therapeutic potential in targeting UPS-related pathologies. Ongoing research aims to clarify its dual roles in promoting or suppressing disease, depending on cellular context.